LDL, HDL, ApoB and Lp(a): what is a cholesterol test counting?
Why can one cholesterol number look fine while another is high?
On this page
Cholesterol is needed by the body, but the particles carrying it in blood and their levels affect cardiovascular risk. LDL and HDL describe cholesterol in different lipoproteins; their roles in transport and plaque formation differ.[1]
What does this actually mean?
The meaning
A cholesterol panel measures lipids carried in the blood. LDL and HDL are types of lipoprotein particles—the carriers—while LDL-C and HDL-C describe cholesterol associated with those carriers. Total cholesterol and non-HDL cholesterol summarize different amounts of cholesterol; they are not separate counts of every particle in the bloodstream.[11]
Different fats, different questions
Triglycerides are another blood fat, used in energy storage. They are not another name for LDL cholesterol. A standard panel can therefore contain several related numbers without each being a competing overall health score. The useful comparison depends on which substance was measured and what clinical question the panel is intended to answer.[8]
Why ApoB appears
ApoB is a protein used to assess the concentration of atherogenic lipoprotein particles—particles involved in artery disease. Cholesterol content per particle varies, so LDL-C and apoB can disagree in an individual. The NLA consensus treats apoB as information that can supplement a standard panel, rather than simply renaming LDL-C.[9]
Why Lp(a) is different
Lipoprotein(a), written Lp(a), is a particular lipoprotein with an additional apolipoprotein(a) component. Its concentration is largely genetically determined. It adds a different risk question to the usual lipid panel; it is not interchangeable with apoB or a readout of what someone ate yesterday. A raised level does not specify when an event will occur.[10]
What the units can hide
LDL-C commonly appears in mg/dL or mmol/L. Lp(a) may appear in mg/dL, a mass concentration, or nmol/L, a particle-related concentration. Lp(a) particle composition varies, so a universal exact conversion between those units is unreliable. Compare the original units with the appropriate guidance rather than entering a bare number into a generic converter.[10]
What to check
Look at the test name and units, whether LDL-C was measured or calculated, and whether fasting was requested for that particular panel. Ask how the results fit age, other risk factors and existing cardiovascular disease. A guideline framework helps make decisions; it cannot turn one lipid value into the same treatment plan for everyone.[11]
What the usual numbers mean
Lipoproteins carry fats and proteins through blood. LDL carries cholesterol and contributes to plaque formation when levels are unhealthy; HDL participates in transporting cholesterol toward the liver. Total cholesterol alone does not show how that total is distributed.[1]
Triglycerides are a different blood fat, reported separately in a standard lipid panel. The panel describes multiple features of lipid metabolism; the results need to be interpreted together with other cardiovascular risk information.[2]
Interpreting a result
Clinical interpretation includes family history, lifestyle, medicines, and conditions that can affect lipids. Very high cholesterol can be inherited, and the absence of symptoms does not settle risk. A provider may request fasting depending on the test and purpose. These details matter when comparing panels, rather than assuming that different testing circumstances or one isolated number are directly interchangeable.[2]
Lifestyle and treatment options
NHLBI describes heart-healthy eating, physical activity, weight management when appropriate, and medicines for relevant lipid problems. Statins, ezetimibe, and PCSK9-directed treatments act through different pathways. Treatments have benefits and adverse effects; choice also depends on other illnesses and whether a person already has cardiovascular disease. Lowering a number is part of the discussion, alongside preventing events and understanding treatment burden.[3]
What changed in the 2026 US society guideline
The 2026 guideline uses PREVENT equations for relevant primary-prevention risk assessment and includes selective coronary calcium information. It recommends measuring lipoprotein(a) at least once and describes ApoB testing as useful in selected situations. LDL and non-HDL goals depend on risk, while established cardiovascular disease has a distinct framework. These refinements add information beyond the standard panel; they are not a universal list of tests to order independently.[4]
Why another recommendation may sound different
USPSTF’s 2022 statin statement addresses adults without established cardiovascular disease and makes decisions according to age, risk factors, and estimated event risk. It excludes known familial hypercholesterolemia and very high LDL from that framework, and identifies uncertainty about starting statins at age 76 or above. Differences from the 2026 society guideline require comparing population, date, and method rather than assuming that one lipid number answers every decision.[5]
High LDL can have an inherited clearance problem
MedlinePlus describes familial hypercholesterolemia, or FH, as an inherited condition that impairs removal of excess cholesterol. LDL receptors help remove LDL particles from blood; variants affecting this pathway can produce high LDL levels and increased early coronary risk. FH is not simply a name for all high cholesterol or proof that someone chose the wrong foods. Assessment still considers family history, clinical findings and other influences.[7]
Inherited mechanisms do not make every case identical
The source describes different genes and inheritance patterns, with some findings affecting one or both gene copies. Genetic and environmental influences can contribute together. These concepts do not calculate an individual’s risk, establish a diagnosis from one LDL result, or provide a current family-screening or pregnancy-treatment plan.[7]
Triglyceride storage and blood levels are related but different concepts
| Concept | Selected NHLBI explanation |
|---|---|
| Energy storage | Unused calories can be stored as triglycerides in fat cells.[8] |
| Blood triglycerides | Triglycerides also circulate in blood and are measured there.[8] |
| Lipid-disorder context | Raised levels can occur alone or with other lipid/metabolic problems.[8] |
A triglyceride result does not isolate one dietary ingredient
NHLBI describes contributions from food and unused calories, alongside genes, medicines, medical conditions and habits. The value is not a direct meter of how much butter was eaten or an independent measure of body-fat mass. Laboratory preparation and the broader health question still matter; the listed causes do not determine a personal treatment choice.[8]
Diagnostic and family testing ask different questions
In East Genomics’ NHS pathway, diagnostic testing investigates suspected familial hypercholesterolaemia when there is no known relative with a confirmed genetic diagnosis. Cascade testing instead follows a confirmed family finding. These are different laboratory requests, not interchangeable broad DNA panels.[12]
The known family finding and relationship matter
The service asks for clinical information and clear indication of a known genetic diagnosis in the family. Eligibility can change. Bringing the family report to the clinical discussion can help identify which question the test should answer; it does not automatically establish anyone’s diagnosis or entitlement to a test.[12]
Evidence & uncertainty
Guidance has scope and date. The 2026 ACC/AHA dyslipidemia guideline and 2022 USPSTF statin recommendation use different frameworks. This overview explains their context; it does not calculate a personal treatment target or independently appraise every therapy.[4][5]
Selected-source overview · Independent review pendingPublished questions
What is the difference between LDL and HDL cholesterol?
Selected-source overview · Independent review pending. Read the evidence context.
They are measurements of cholesterol carried in different lipoproteins. LDL contributes to plaque formation at unhealthy levels; HDL participates in transport toward the liver.[1]
Evidence behind this answer
- Blood Cholesterol: What Is Blood Cholesterol?
agency explanation · Date not stated
Selected page text; cited sections · Lipoproteins, plaque, inherited and other causes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Are triglycerides the same as cholesterol?
Selected-source overview · Independent review pending. Read the evidence context.
No. They are a different type of blood fat and are reported separately in a lipid panel.[2]
Evidence behind this answer
- Blood Cholesterol: Diagnosis
agency explanation · Date not stated
Selected page text; cited sections · Lipid panel, LDL, HDL, triglycerides and clinical context
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does every cholesterol blood test require fasting?
Selected-source overview · Independent review pending. Read the evidence context.
NHLBI says a provider may request fasting before a lipoprotein panel. The need depends on the planned test and its clinical purpose.[2]
Evidence behind this answer
- Blood Cholesterol: Diagnosis
agency explanation · Date not stated
Selected page text; cited sections · Lipid panel, LDL, HDL, triglycerides and clinical context
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Why do Lp(a) and ApoB appear in newer cholesterol guidance?
Selected-source overview · Independent review pending. Read the evidence context.
The 2026 society guideline uses Lp(a) to identify additional risk and ApoB in selected settings where the standard profile may miss relevant lipoprotein-related risk.[4]
Evidence behind this answer
- Top Things to Know: 2026 Guideline on the Management of Dyslipidemia
professional guideline summary · 2026-03-13
Official society summary; full guideline not independently appraised · Items 1–10: PREVENT, Lp(a), ApoB, treatment goals and risk
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does one cholesterol result determine the same treatment for everyone?
Selected-source overview · Independent review pending. Read the evidence context.
No. NHLBI describes a discussion involving cardiovascular risk, other conditions, lifestyle, medicines, benefits, and adverse effects.[3]
Evidence behind this answer
- Blood Cholesterol: Treatment
agency explanation · Date not stated
Selected page text; cited sections · Lifestyle and medicine classes; discussion of harms
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
What uncertainty does USPSTF identify about starting statins after age 75?
Selected-source overview · Independent review pending. Read the evidence context.
For primary prevention at age 76 or above, its 2022 statement finds insufficient evidence to assess the balance of benefits and harms of starting treatment.[5]
Evidence behind this answer
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
professional guideline · 2022-08-23
Selected recommendation text · Recommendation summary; population and exclusions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Who is PREVENT-ASCVD intended to assess in the 2026 lipid framework?
Selected-source overview · Independent review pending. Read the evidence context.
The guideline-author release describes adults aged 30–79 without known ASCVD or subclinical atherosclerosis and with LDL-C 70–189 mg/dL. It estimates risk to guide primary prevention; existing cardiovascular disease and other special situations have different pathways.[6]
Evidence behind this answer
- ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol
professional explanation · 2026-03-13
Selected official page text; cited sections · PREVENT-ASCVD scope; primary/secondary prevention; inclisiran outcome evidence
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
What do primary and secondary prevention mean?
Selected-source overview · Independent review pending. Read the evidence context.
Primary prevention aims to prevent a first cardiovascular event. Secondary prevention concerns people who already have atherosclerotic cardiovascular disease, with treatment intended to prevent further events. Their risk and treatment frameworks differ.[6]
Evidence behind this answer
- ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol
professional explanation · 2026-03-13
Selected official page text; cited sections · PREVENT-ASCVD scope; primary/secondary prevention; inclisiran outcome evidence
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does lowering LDL prove that every treatment prevents heart attacks?
Selected-source overview · Independent review pending. Read the evidence context.
The 2026 guideline-author release says inclisiran lowers LDL, while trials were still assessing whether it improves cardiovascular outcomes. Evidence for a biomarker change and evidence for fewer clinical events are distinct questions.[6]
Evidence behind this answer
- ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol
professional explanation · 2026-03-13
Selected official page text; cited sections · PREVENT-ASCVD scope; primary/secondary prevention; inclisiran outcome evidence
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is LDL just bad cholesterol, or is that shorthand hiding something important?
Selected-source overview · Independent review pending. Read the evidence context.
The label is shorthand. LDL is a lipoprotein particle carrying cholesterol; LDL-C reports the cholesterol carried in those particles. Cholesterol also has normal biological roles. Elevated LDL-related exposure contributes to plaque and cardiovascular risk, but 'bad' and 'good' labels alone do not describe the complete lipid profile, overall risk or the effects of a specific treatment.[1][6]
Evidence behind this answer
- Blood Cholesterol: What Is Blood Cholesterol?
agency explanation · Date not stated
Selected page text; cited sections · Lipoproteins, plaque, inherited and other causes - ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol
professional explanation · 2026-03-13
Selected official page text; cited sections · PREVENT-ASCVD scope; primary/secondary prevention; inclisiran outcome evidence
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
How do clinicians think about cholesterol risk differently from one flagged lab number?
Selected-source overview · Independent review pending. Read the evidence context.
Clinicians interpret a lipid profile alongside age, blood pressure, smoking, diabetes, family history and existing cardiovascular disease, rather than treating a flag as the entire risk assessment. Measurement context and follow-up also matter. Expected absolute benefit depends on baseline risk, with benefits weighed against adverse effects. A general risk framework does not select an individual's treatment.[3][2][5]
Evidence behind this answer
- Blood Cholesterol: Treatment
agency explanation · Date not stated
Selected page text; cited sections · Lifestyle and medicine classes; discussion of harms - Blood Cholesterol: Diagnosis
agency explanation · Date not stated
Selected page text; cited sections · Lipid panel, LDL, HDL, triglycerides and clinical context - Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
professional guideline · 2022-08-23
Selected recommendation text · Recommendation summary; population and exclusions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does familial hypercholesterolemia simply mean eating too much dietary cholesterol?
Selected-source overview · Independent review pending. Read the evidence context.
No. MedlinePlus describes an inherited problem in cholesterol-removal pathways, with other influences also relevant.[7]
Evidence behind this answer
- Familial hypercholesterolemia
agency explanation · 2020
Selected relevant original page passages inspected · Inherited clearance mechanism, genes, patterns and other influences
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is familial hypercholesterolemia the explanation for every high-cholesterol result?
Selected-source overview · Independent review pending. Read the evidence context.
No. The cited source distinguishes FH from the wider range of high-cholesterol cases.[7]
Evidence behind this answer
- Familial hypercholesterolemia
agency explanation · 2020
Selected relevant original page passages inspected · Inherited clearance mechanism, genes, patterns and other influences
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can unused calories contribute to triglyceride storage even beyond a single fatty food?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. NHLBI describes unused calories being stored as triglycerides; multiple factors affect blood levels.[8]
Evidence behind this answer
- High Blood Triglycerides
agency explanation · Date not stated
Selected relevant original page passages inspected · Triglycerides as stored energy and circulating lipid; multiple influences and overlapping disorders
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can high triglycerides occur with other lipid or metabolic problems?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. NHLBI describes both stand-alone and overlapping lipid-disorder contexts.[8]
Evidence behind this answer
- High Blood Triglycerides
agency explanation · Date not stated
Selected relevant original page passages inspected · Triglycerides as stored energy and circulating lipid; multiple influences and overlapping disorders
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
How can LDL cholesterol and ApoB disagree?
Selected-source overview · Independent review pending. Read the evidence context.
They measure related but different features: cholesterol carried in LDL versus a protein marker of atherogenic particle concentration. The cholesterol carried per particle varies. Discordance can therefore carry useful risk information and deserves interpretation alongside the full panel, rather than assuming one test must be wrong.[9]
Evidence behind this answer
- Role of apolipoprotein B in the clinical management of cardiovascular risk in adults
professional consensus · 2024
Original professional-society highlights and abstract inspected · Highlights and original consensus abstract: apoB, LDL-C discordance and risk
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can I compare Lp(a) results in mg/dL and nmol/L using one exact multiplier?
Selected-source overview · Independent review pending. Read the evidence context.
No universal exact factor works for everyone because Lp(a) particle composition varies. Keep the original result and units and use guidance appropriate to that measurement. A converted estimate can create false precision, especially near a decision boundary.[10]
Evidence behind this answer
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: an EAS consensus statement
professional consensus · 2022
Indexed original consensus PDF passages inspected · Measurement and reporting units; genetically determined concentration
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is testing a known family cholesterol finding the same as ordering a broad DNA panel?
Selected-source overview · Independent review pending. Read the evidence context.
No. The NHS service distinguishes investigating a suspected diagnosis from cascade testing after a confirmed family finding. The clinical details and known report guide the request.[12]
Evidence behind this answer
- Making the best use of familial hypercholesterolaemia (FH) genomic testing
official genomic service guidance · 2025
Complete substantive original service notice read. Distinct diagnostic/cascade laboratory pathways and need for known family finding adopted. Eligibility scores, test-order form instructions and a universal genomic-test rule not adopted. · July 17, 2025 Diagnostic testing and Cascade testing; clinical details/eligibility paragraphs
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
What this overview has not resolved
Further work is needed on absolute event reductions and harms by treatment and baseline risk; familial hypercholesterolemia and pregnancy-specific care; other countries’ lipid guidelines.
References
- Blood Cholesterol: What Is Blood Cholesterol?
Agency explanation
NHLBI · Content/publication date: not stated
Accessed: 2026-10-06 UTC · Selected page text; cited sections
Cited sections: Lipoproteins, plaque, inherited and other causes - Blood Cholesterol: Diagnosis
Agency explanation
NHLBI · Content/publication date: not stated
Accessed: 2026-10-06 UTC · Selected page text; cited sections
Cited sections: Lipid panel, LDL, HDL, triglycerides and clinical context - Blood Cholesterol: Treatment
Agency explanation
NHLBI · Content/publication date: not stated
Accessed: 2026-10-06 UTC · Selected page text; cited sections
Cited sections: Lifestyle and medicine classes; discussion of harms - Top Things to Know: 2026 Guideline on the Management of Dyslipidemia
Professional guideline summary
American Heart Association / ACC and partner societies · Content/publication date: 2026-03-13
Accessed: 2026-10-06 UTC · Official society summary; full guideline not independently appraised
Cited sections: Items 1–10: PREVENT, Lp(a), ApoB, treatment goals and risk - Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
Professional guideline
US Preventive Services Task Force · Content/publication date: 2022-08-23
Accessed: 2026-10-06 UTC · Selected recommendation text
Cited sections: Recommendation summary; population and exclusionsPrimary prevention scope; not a recommendation for every lipid disorder.
- ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol
Professional explanation
American Heart Association / ACC · Content/publication date: 2026-03-13
Accessed: 2026-10-06 UTC · Selected official page text; cited sections
Cited sections: PREVENT-ASCVD scope; primary/secondary prevention; inclisiran outcome evidenceOfficial guideline-author release; not an independent appraisal of all treatment trials.
- Familial hypercholesterolemia
Agency explanation
MedlinePlus Genetics · Content/publication date: 2020
Accessed: 2026-10-07 UTC · Selected relevant original page passages inspected
Cited sections: Inherited clearance mechanism, genes, patterns and other influencesPage footer January 1, 2020, with later references including a 2025 GeneReviews update. Selected mechanism/inheritance concepts; no current prevalence estimate, diagnostic threshold, cascade-screening pathway or drug recommendation extracted.
- High Blood Triglycerides
Agency explanation
NHLBI · Content/publication date: not stated
Accessed: 2026-10-07 UTC · Selected relevant original page passages inspected
Cited sections: Triglycerides as stored energy and circulating lipid; multiple influences and overlapping disordersSelected concepts. Numerical categories, pancreatitis thresholds, diet doses, medicine choices and comparative cardiovascular effects not extracted.
- Role of apolipoprotein B in the clinical management of cardiovascular risk in adults
Professional consensus
National Lipid Association · Content/publication date: 2024
Accessed: 2026-10-15 UTC · Original professional-society highlights and abstract inspected
Cited sections: Highlights and original consensus abstract: apoB, LDL-C discordance and risk - Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: an EAS consensus statement
Professional consensus
European Atherosclerosis Society · Content/publication date: 2022
Accessed: 2026-10-15 UTC · Indexed original consensus PDF passages inspected
Cited sections: Measurement and reporting units; genetically determined concentration - Lipid profile test
Agency condition or prevention explanation
NIH / National Library of Medicine · Content/publication date: not stated
Accessed: 2026-10-15 UTC · Indexed original official encyclopedia passages inspected
Cited sections: Components and purpose of a lipid panel - Making the best use of familial hypercholesterolaemia (FH) genomic testing
Official genomic service guidance
East Genomics, NHS · Content/publication date: 2025
Accessed: 2026-10-20 UTC · Complete substantive original service notice read. Distinct diagnostic/cascade laboratory pathways and need for known family finding adopted. Eligibility scores, test-order form instructions and a universal genomic-test rule not adopted.
Cited sections: July 17, 2025 Diagnostic testing and Cascade testing; clinical details/eligibility paragraphsEngland service example; eligibility and pathways can change.
Scope & review
- Population
- General adult readers; guidance populations explicitly distinguished
- Exposure or intervention
- Blood lipids/testing, familial cholesterol-clearance mechanisms, triglycerides and lipid-lowering categories
- Comparison
- Different lipid concepts and dated US recommendation frameworks; no current FH cascade-screening or gene-specific treatment comparison
- Outcomes
- Risk and mechanism literacy; not all high LDL is FH and one triglyceride value does not identify a dietary cause
- Timeframe
- Earlier guidance snapshot through 2026-10-06 plus selected 2026-10-07 mechanism checks; older source dates retained
- Jurisdiction
- Selected US educational/agency explanations and earlier US professional guidance
Selected-source educational overview. Cited agency explanations, professional summaries, and study material were read to the extent recorded beside each source. No exhaustive literature search, independent systematic synthesis, formal certainty grade, or qualified review was performed. Edition 3.13 adds selected foundational health, genetics and access explanations and scoped introductory links; older reference access dates remain explicit.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-06 UTC: Selected-source explainer and authored reader questions added; independent review pending.
- 2026-10-06 UTC: Added related reading and made remaining editorial scope explicit in edition 3.1; source-access dates retained.
- 2026-10-07 UTC: Edition 3.13: added selected foundational health, genetics and access definitions, comparisons and sourced questions. Earlier anchors and access dates retained; qualified review remains pending.
- 2026-10-15 UTC: Added the plain-English series explanation with definitions, distinctions, practical questions and selected primary sources; qualified review remains pending.
- 2026-10-20 UTC: Added bounded foundational distinctions and selected original comparison or official safety explanations. Preserved prior prose and pending qualified-review status; original-source access and applicability limits are recorded.
What this article still leaves open
- absolute event reductions and harms by treatment and baseline risk
- familial hypercholesterolemia and pregnancy-specific care
- other countries’ lipid guidelines
- Current FH diagnostic/family-screening pathways, condition-specific triglyceride evaluation, pregnancy care and absolute treatment benefits/harms.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
More in the plain-English series
Keep making sense of it.
Explore Prevention & care explanations See every explanationExplore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.